 Shares of Moderna Inc. MRNA, 3.94 were up about 1.0 in premarket trading on Monday after the company reiterated that it expects to have 5.0 billion in sales of its COVID-19 vaccine in 2023. Moderna also said its vaccine generated 18.4 billion in sales in 2022, and the company plans to boost spending on research and development to 4.5 billion this year, up from 3.3 billion in 2022. 